Concentration of enkephalins in cerebrospinal fluid of patients after severe head injury

Neuropeptides

Volumn 31, Issue 1, 1997, Pages 78-81

  Stachura, Z ^a   Kowalski, J ^a   Obuchowicz, E ^a   Huzarska, M ^a   Herman, Z S ^a  

^a UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE ENKEPHALIN; METENKEPHALIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD INJURY; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031058712     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90024-X     Document Type: Article

References (19)

1. Akil H, Watson S, Sulliran S et al. Enkephalin-like material in normal human CSF. Life Sci 1978; 23: 121-126.
2. Sandor P, De Jong W, De Wied D. Endorphinergic mechanisms in cerebral blood flow autoregulation. Brain Res 1986; 386: 122-129.
3. Bradley P B, Brookes A. A microiontophoretic study of the actions of mu-, delta-, and kappa-opiate receptor agonists in the rat brain. Br J Pharmacol 1984; 83: 763-772.
4. Atweh S, Kumar M. Distribution and significance of opioid receptors in the brain. Br Med Bull 1983; 39: 47-52.
5. Baskin D, Hosobuchi Y. Naloxone reversal of ischaemic neurological deficits in man. Lancet 1981; 2: 272-275.
6. Nappi G, Facchinetti F, Bono G et al. CSF and plasma levels of proopiomelanocortin-related peptides in reversible ischaemic attacks and strokes. J Neurol Neurosurg Psychiatry 1986; 49: 17-21.
7. Wesche D, Hollt V, Hertz A. Radioimmunoassay of enkephalins. Naunyn Schmiedeberg's Arch Pharmacol 1977; 301: 79-82.
8. Cupo A, Jarry Th. Detection of methionine-enkephalin at the 10-16 level. J Neuroimmunol 1985; 8: 57-67.
9. Sjostrom S, Tamsen A, Hartvig P et al. Cerebrospinal fluid concentrations of substance P and met-enkephalin Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg 1988; 67: 976-981.
10. Vecsei L, Widerlov R, Ekman R et al. Suboccipital cerebrospinal fluid and plasma concentrations of somatostatin, neuropeptide Y and beta-endorphin in patients with common migraine. Neuropeptides 1992; 22: 111-116.
11. Faden A, Molineaux C, Rosenberger J et al. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Regul Pept 1985; 11: 35-41.
12. Faden A, Jacobs T. Dynorphin induced partially reversible paraplegia in the rat. Eur J Pharmacol 1983; 91(2-3): 321-324.
13. Faden A, Jacobs T. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opioid action. Br J Pharmacol 1984; 81: 271-276.
14. McIntosh T. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: a review. J Neurotrauma 1993; 10: 215-261.
15. Flamm E, Young W, Collins W et al. A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg 1985; 63: 390-397.
16. Hayes R, Lyeth B, Jenkins L et al. Possible protective effect of endogenous opioids in traumatic brain injury. J Neurosurg 1990; 72: 252-261.
17. Terenius L, Nyberg F. Opioid peptides in man-analytical aspects. Life Sci 1987; 41: 805-808.
18. Lyeth B G, Jiang J Y, Gong Q-Z et al. Effects of mu opioid agonist and antagonist on neurological outcome following traumatic brain injury in the rat. Neuropeptides 1995; 29: 11-19.
19. Marshall K, Schlesinger M, Turndorf H et al. Beta-endorphin and ACTH levels in the perioperative period. Gen Pharmacol 1989; 20: 399-402.